by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersThrivelab Co. dba Thrivelab

All Warning Letters

Thrivelab Co. dba Thrivelab

Warning LetterOpen

Recipient Title Founder and Chief Executive Officer, 701 North Green Valley Parkway, Suite #213 Henderson , NV 89074-6177 United StatesIssued Jun 8, 2026Center for Drug Evaluation and Research (CDER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateJun 8, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Thrivelab Co. dba Thrivelab
Location: Recipient Title Founder and Chief Executive Officer, 701 North Green Valley Parkway, Suite #213 Henderson , NV 89074-6177 United States
FEI Number: N/A
Country: United States
Issue Date: June 08, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Subject

False & Misleading Claims/Misbranded (Telehealth)

Thrivelab Co. dba Thrivelab FDA Warning Letter, June 8, 2026